Background.jpg
Background.jpg

Intro


THE FUTURE OF DIGITAL MOLECULAR Dx

 

SCROLL DOWN

Intro


THE FUTURE OF DIGITAL MOLECULAR Dx

 

REAGENT-FREE POINT OF CARE PLATFORM

SIME Dx WAS FOUNDED BY WORLD-RENOWNED SCIENTISTS TO REALISE THE POTENTIAL
OF PHOTONICS AND MACHINE LEARNING IN CLINICAL DIAGNOSTICS. 


DIGITAL MOLECULAR DIAGNOSTICS

THE DMDx PLATFORM MEASURES MULTIPLE BIOMARKERS FROM A SINGLE FLUID SAMPLE IN REAL TIME. GENERATING A UNIQUE MOLECULAR SIGNATURE OF A PATIENT AT THAT MOMENT IN TIME - A SNAPSHOT OF THEIR HEALTH. THIS SIGNATURE IS RAPIDLY ANALYSED TO DELIVER PRECISE RESULTS TO CLINICIANS IN CRITICAL MOMENTS.  

Technology


LIVING DATA
POWERED BY
MACHINE LEARNING

Technology


LIVING DATA
POWERED BY
MACHINE LEARNING

the DMDx PATENTED PLATFORM BRINGS DATA TO LIFE 


DMDx PLATFORM

When a sample is analysed by the DMDx platform a unique biochemical signature is produced. This signature is stored in a central server along with encrypted clinical outcomes data.

MACHINE LEARNING

The database will pair a patient's unique biochemical signature to their outcomes data. Machine learning will then be applied to train our algorithms, and continually refine the test.

BIOMARKER DISCOVERY

Over time as the database grows machine learning will recognise new patterns. This could potentially enable us to discover new biomarkers and platform applications.

 
 

...STARTING AT BIRTH

The first application on the DMDx platform is a Neonatal Lung Maturity Test (LMT)